GB2474209A - Sertraline composition - Google Patents

Sertraline composition Download PDF

Info

Publication number
GB2474209A
GB2474209A GB1102349A GB201102349A GB2474209A GB 2474209 A GB2474209 A GB 2474209A GB 1102349 A GB1102349 A GB 1102349A GB 201102349 A GB201102349 A GB 201102349A GB 2474209 A GB2474209 A GB 2474209A
Authority
GB
United Kingdom
Prior art keywords
sertraline
composition
sertraline composition
salt
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB1102349A
Other versions
GB2474209B (en
GB201102349D0 (en
Inventor
Ingrid Soderberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosemont Pharmaceuticals Ltd
Original Assignee
Rosemont Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosemont Pharmaceuticals Ltd filed Critical Rosemont Pharmaceuticals Ltd
Publication of GB201102349D0 publication Critical patent/GB201102349D0/en
Publication of GB2474209A publication Critical patent/GB2474209A/en
Application granted granted Critical
Publication of GB2474209B publication Critical patent/GB2474209B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A sertraline composition is provided that is suitable for oral administration in a patient. The composition contains a pharmaceutically acceptable salt of sertraline and at least one suspension agent to allow the sertraline salt to be substantially suspended in solution.
GB1102349.6A 2008-08-07 2009-07-08 Sertraline composition Active GB2474209B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0814466.9A GB0814466D0 (en) 2008-08-07 2008-08-07 Sertraline composition
PCT/GB2009/001700 WO2010015797A1 (en) 2008-08-07 2009-07-08 Sertraline composition

Publications (3)

Publication Number Publication Date
GB201102349D0 GB201102349D0 (en) 2011-03-30
GB2474209A true GB2474209A (en) 2011-04-06
GB2474209B GB2474209B (en) 2012-02-22

Family

ID=39767674

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0814466.9A Ceased GB0814466D0 (en) 2008-08-07 2008-08-07 Sertraline composition
GB1102349.6A Active GB2474209B (en) 2008-08-07 2009-07-08 Sertraline composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB0814466.9A Ceased GB0814466D0 (en) 2008-08-07 2008-08-07 Sertraline composition

Country Status (2)

Country Link
GB (2) GB0814466D0 (en)
WO (1) WO2010015797A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0768083A2 (en) * 1995-07-17 1997-04-16 Pfizer Inc. The use of sertraline to treat post myocardial infarction patients
WO1999062522A1 (en) * 1998-05-29 1999-12-09 Eli Lilly And Company Combination therapy for treatment of bipolar disorders
US20050070577A1 (en) * 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
US20070213562A1 (en) * 2006-01-23 2007-09-13 Ami Zoran Recycling process for preparing sertraline
US20070215511A1 (en) * 2006-03-16 2007-09-20 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
WO2008020150A1 (en) * 2006-08-18 2008-02-21 Syngenta Limited Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117911A2 (en) * 2004-05-06 2005-12-15 Cydex, Inc. Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0768083A2 (en) * 1995-07-17 1997-04-16 Pfizer Inc. The use of sertraline to treat post myocardial infarction patients
WO1999062522A1 (en) * 1998-05-29 1999-12-09 Eli Lilly And Company Combination therapy for treatment of bipolar disorders
US20050070577A1 (en) * 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
US20070213562A1 (en) * 2006-01-23 2007-09-13 Ami Zoran Recycling process for preparing sertraline
US20070215511A1 (en) * 2006-03-16 2007-09-20 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
WO2008020150A1 (en) * 2006-08-18 2008-02-21 Syngenta Limited Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs

Also Published As

Publication number Publication date
GB2474209B (en) 2012-02-22
GB0814466D0 (en) 2008-09-10
GB201102349D0 (en) 2011-03-30
WO2010015797A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
UA106636C2 (en) MORPHOLINOTIAZOLES AS A POSITIVE ALLOSTERIC ALPHA MODULATORS 7
MY173215A (en) Acetylcysteine compositions and methods of use thereof
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
MX363023B (en) Oral formulations of cytidine analogs and methods of use thereof.
MX2014001101A (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods.
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
TR201900199T4 (en) Immediate release pharmaceutical compositions containing oxycodone and naloxone.
MX2011011109A (en) Oral formulations of bendamustine.
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
ZA201206360B (en) Solid composition for the oral administration of dyes and diagnostic use thereof
MX2012006320A (en) Amantadine compositions and methods of use.
NZ576424A (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
MX2010005198A (en) Pharmaceutical compositions.
IL202111A0 (en) Formulations for the oral administration of therapeutic agents and related methods
NZ596851A (en) Methods of treating hepatic encephalopathy
WO2010089259A3 (en) Sustained release composition containing quetiapine
GB2474209A (en) Sertraline composition
IN2014CN04119A (en)
WO2012134590A3 (en) Calcium supplement
MX2015006217A (en) Dispersible tablet.
IL218526A0 (en) Use of indole derivatives as nurr-1 activators for the application thereof as a medicament for the treatment of parkinson's disease
MD3987C2 (en) Use of Diosmine for the treatment of advancing hepatic cirrhosis associated with cardiac insufficiency
MD3986C2 (en) Use of Diosmine for the treatment of portal gastropathies in the hepatic cirrhosis